Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences' Chief Financial Officer Robin Washington to Step Down in Early 2020

Business Wire April 30, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

Business Wire April 25, 2019

Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities

Business Wire April 24, 2019

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019

Business Wire April 18, 2019

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

Business Wire April 16, 2019

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

Business Wire April 12, 2019

Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019

Business Wire April 11, 2019

The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Benzinga.com  April 11, 2019

Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019

Business Wire April 11, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Business Wire April 9, 2019

Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis

Business Wire April 5, 2019

The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Benzinga.com  March 29, 2019

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS

GlobeNewswire March 28, 2019

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

Business Wire March 28, 2019

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY

GlobeNewswire March 28, 2019

Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia

Business Wire March 28, 2019

The Precision Biosciences IPO: What You Need To Know

Benzinga.com  March 27, 2019

Option-trading opportunities on Carnival Corp., Facebook Inc., Gilead Sciences Inc., Lennar Corp., and Visa Inc.

PR Newswire March 27, 2019

Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019

Business Wire March 27, 2019

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Business Wire March 26, 2019